Correction to: Cancer Cell Int (2021) 21:426 https://doi.org/10.1186/s12935-021-02100-w
Following the publication of the original article [1], we were notified that the affiliation of the third author was incorrect.
Originally published affiliation: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
Corrected affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
The original article has been corrected.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Huihui Jiang, Aiqun Xu and Wanli Xia contributed equally to this work
Contributor Information
Sijing Zhou, Email: zhousijing@yeah.net.
Ran Wang, Email: wangran@ahmu.edu.cn.
Reference
- 1.Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, Zhu K, Zhou S, Wang R. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell Int. 2021;21:426. doi: 10.1186/s12935-021-02100-w. [DOI] [PMC free article] [PubMed] [Google Scholar]